세계의 약물감시 시장(2025-2035년): 산업 분석, 시장 규모, 점유율, 성장, 동향, 예측 - 단계별(전임상, 1상, 2상, 3상, 4상), 유형별, 치료영역별, 최종용도별, 기타
Pharmacovigilance Market (Phase: Pre-clinical, Phase I, Phase II, Phase III and Phase IV); Type: Therapeutic Area, and End-use, and Others - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035
상품코드:1769903
리서치사:Transparency Market Research
발행일:2025년 05월
페이지 정보:영문 228 Pages
라이선스 & 가격 (부가세 별도)
한글목차
약물감시 시장 - 분석 범위
TMR의 조사 보고서 '세계의 약물감시 시장'은 2025년부터 2035년까지의 예측 기간 동안 시장 지표에 관한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회에 대해서도 조사했습니다. 2025년을 기준연도, 2035년을 예측연도로 하여 2019년부터 2035년까지 세계의 약물감시 시장의 수익과 예측을 제공합니다.
이 보고서는 광범위한 조사를 거쳐 작성되었으며, 1차 조사에서는 분석가가 KOL(Key Opinion Leader), 업계 리더, 의사결정자와의 인터뷰를 실시했습니다.
시장 개황
시장 규모(2024년)
83억 달러
시장 규모(2035년)
194억 달러
CAGR
7.9%
본 보고서에서는 세계의 약물감시 시장 경쟁 구도에 대해 분석했습니다.
목차
제1장 서론
제2장 전제조건과 분석방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
소개
개요
시장 역학
세계의 약물감시 시장 분석과 예측(2020-2035년)
제5장 주요 인사이트
의약품의 안전한 사용에 관한 정부의 대처의 개요
주요 지역/국가별 약물 유해 반응 발생률
지역/국가별 규제 시나리오
의약품 개발 프로세스에서의 역할
약물감시에서 사용한 보고서의 비교 분석
자금 조달 및 투자
주요 업계 이벤트(합병, 인수, 제휴, 협업 등)
Porter's Five Forces 분석
PESTEL 분석
밸류체인 분석
제6장 세계 시장의 분석과 예측 : 단계별
소개 및 정의
주요 분석결과/진전
시장 예측(금액 기준) : 단계별(2020-2035년)
전임상
1상
2상
3상
4상
시장 매력 분석 : 단계별
제7장 세계 시장의 분석과 예측 : 유형별
소개 및 정의
주요 분석결과/진전
시장 예측(금액 기준) : 유형별(2020-2035년)
자발적인 보고
타겟 보고서
코호트 이벤트 모니터링
역학 연구
시판 후 조사
시장 매력 분석 : 유형별
제8장 세계 시장의 분석과 예측 : 제공 모드별
소개 및 정의
주요 분석결과/진전
시장 예측(금액 기준) : 제공 모드별(2020-2035년)
사내
수탁계약
시장 매력 분석 : 제공 모드별
제9장 세계 시장의 분석과 예측 : 치료영역별
소개 및 정의
주요 분석결과/진전
시장 예측(금액 기준) : 치료영역별(2020-2035년)
종양
신경학
심장병학
호흡기계
자가면역질환
기타
시장 매력 분석 : 치료영역별
제10장 세계 시장 분석 및 예측 : 최종사용자별
소개 및 정의
주요 분석결과/진전
시장 예측(금액 기준) : 최종사용자별(2020-2035년)
제약 및 생명공학 기업
CRO(의약품 개발 업무 수탁 기관)
기타
시장 매력 분석 : 최종사용자별
제11장 세계 시장 분석 및 예측 : 지역별
주요 분석결과
시장 예측(금액 기준) : 지역별
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장 매력 분석 : 지역별
제12장 북미 시장의 분석과 예측
제13장 유럽 시장의 분석과 예측
제14장 아시아태평양시장의 분석과 예측
제15장 라틴아메리카 시장의 분석과 예측
제16장 중동 및 아프리카 시장의 분석과 예측
제17장 경쟁 구도
시장 기업 및 경쟁 매트릭스(기업의 계층별 및 규모별)
시장 점유율 분석 : 기업별(2024년)
기업 프로파일
Accenture
IQVIA Inc.
Cognizant
Linical
ArisGlobal
ITClinical
ICON plc.
TAKE Solutions Limited
Parexel International(MA) Corporation
Wipro
United BioSource LLC
Ergomed Group
Quanticate
CSM
영문 목차
영문목차
Pharmacovigilance Market - Scope of Report
TMR's report on the global pharmacovigilance market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global pharmacovigilance market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pharmacovigilance market from 2025 to 2035.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the pharmacovigilance market.
Market Snapshot
Market Value in 2024
US$ 8.3 Bn
Market Value in 2035
US$ 19.4 Bn
CAGR
7.9%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pharmacovigilance market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global pharmacovigilance market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pharmacovigilance market.
The report delves into the competitive landscape of the global pharmacovigilance market. Key players operating in the global pharmacovigilance market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global pharmacovigilance market profiled in this report.
Key Questions Answered in Global pharmacovigilance Market Report:
What is the sales/revenue generated by pharmacovigilance across all regions during the forecast period?
What are the opportunities in the global pharmacovigilance market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Pharmacovigilance Market - Research Objectives and Research Approach
The comprehensive report on the global pharmacovigilance market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global pharmacovigilance market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pharmacovigilance market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pharmacovigilance Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pharmacovigilance Market Analysis and Forecast, 2020 to 2035
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Overview of Government Initiatives in Safe Medicine Use
5.2. Rate of Adverse Drug Reactions By Key Region/Countries
5.3. Regulatory Scenario by Region/Country
5.4. Role of Pharmacovigilance during Drug Development Process
5.5. Comparative Analysis of Report used in Pharmacovigilance
5.6. Funding and Investments
5.7. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
5.8. PORTER's Five Forces Analysis
5.9. PESTEL Analysis
5.10. Value Chain Analysis
6. Global Pharmacovigilance Market Analysis and Forecast, by Phase
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Phase, 2020 to 2035
6.3.1. Pre-clinical
6.3.2. Phase I
6.3.3. Phase II
6.3.4. Phase III
6.3.5. Phase IV
6.4. Market Attractiveness Analysis, by Phase
7. Global Pharmacovigilance Market Analysis and Forecast, by Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Type, 2020 to 2035
7.3.1. Spontaneous Reporting
7.3.2. Targeted Reporting
7.3.3. Cohort Event Monitoring
7.3.4. Epidemiological Studies
7.3.5. Post-Marketing Surveillance
7.4. Market Attractiveness Analysis, by Type
8. Global Pharmacovigilance Market Analysis and Forecast, by Delivery Mode
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Delivery Mode, 2020 to 2035
8.3.1. In-house
8.3.2. Contract Outsourcing
8.4. Market Attractiveness Analysis, by Delivery Mode
9. Global Pharmacovigilance Market Analysis and Forecast, by Therapeutic Area
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Therapeutic Area, 2020 to 2035
9.3.1. Oncology
9.3.2. Neurology
9.3.3. Cardiology
9.3.4. Respiratory Systems
9.3.5. Autoimmune Diseases
9.3.6. Others
9.4. Market Attractiveness Analysis, by Therapeutic Area
10. Global Pharmacovigilance Market Analysis and Forecast, by End-user
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by End-user, 2020 to 2035
10.3.1. Pharmaceutical & Biotechnology Companies
10.3.2. Contract Research Organizations (CROs)
10.3.3. Others
10.4. Market Attractiveness Analysis, by End-user
11. Global Pharmacovigilance Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2020 to 2035
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Pharmacovigilance Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Phase, 2020 to 2035
12.2.1. Pre-clinical
12.2.2. Phase I
12.2.3. Phase II
12.2.4. Phase III
12.2.5. Phase IV
12.3. Market Value Forecast, by Type, 2020 to 2035
12.3.1. Spontaneous Reporting
12.3.2. Targeted Reporting
12.3.3. Cohort Event Monitoring
12.3.4. Epidemiological Studies
12.3.5. Post-Marketing Surveillance
12.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
12.4.1. In-house
12.4.2. Contract Outsourcing
12.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
12.5.1. Oncology
12.5.2. Neurology
12.5.3. Cardiology
12.5.4. Respiratory Systems
12.5.5. Autoimmune Diseases
12.5.6. Others
12.6. Market Value Forecast, by End-user, 2020 to 2035
12.6.1. Pharmaceutical & Biotechnology Companies
12.6.2. Contract Research Organizations (CROs)
12.6.3. Others
12.7. Market Value Forecast, by Country, 2020 to 2035
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Phase
12.8.2. By Type
12.8.3. By Delivery Mode
12.8.4. By Therapeutic Area
12.8.5. By End-user
12.8.6. By Country
13. Europe Pharmacovigilance Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Phase, 2020 to 2035
13.2.1. Pre-clinical
13.2.2. Phase I
13.2.3. Phase II
13.2.4. Phase III
13.2.5. Phase IV
13.3. Market Value Forecast, by Type, 2020 to 2035
13.3.1. Spontaneous Reporting
13.3.2. Targeted Reporting
13.3.3. Cohort Event Monitoring
13.3.4. Epidemiological Studies
13.3.5. Post-Marketing Surveillance
13.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
13.4.1. In-house
13.4.2. Contract Outsourcing
13.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
13.5.1. Oncology
13.5.2. Neurology
13.5.3. Cardiology
13.5.4. Respiratory Systems
13.5.5. Autoimmune Diseases
13.5.6. Others
13.6. Market Value Forecast, by End-user, 2020 to 2035
13.6.1. Pharmaceutical & Biotechnology Companies
13.6.2. Contract Research Organizations (CROs)
13.6.3. Others
13.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
13.7.1. Germany
13.7.2. UK
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Phase
13.8.2. By Type
13.8.3. By Delivery Mode
13.8.4. By Therapeutic Area
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific Pharmacovigilance Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Phase, 2020 to 2035
14.2.1. Pre-clinical
14.2.2. Phase I
14.2.3. Phase II
14.2.4. Phase III
14.2.5. Phase IV
14.3. Market Value Forecast, by Type, 2020 to 2035
14.3.1. Spontaneous Reporting
14.3.2. Targeted Reporting
14.3.3. Cohort Event Monitoring
14.3.4. Epidemiological Studies
14.3.5. Post-Marketing Surveillance
14.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
14.4.1. In-house
14.4.2. Contract Outsourcing
14.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
14.5.1. Oncology
14.5.2. Neurology
14.5.3. Cardiology
14.5.4. Respiratory Systems
14.5.5. Autoimmune Diseases
14.5.6. Others
14.6. Market Value Forecast, by End-user, 2020 to 2035
14.6.1. Pharmaceutical & Biotechnology Companies
14.6.2. Contract Research Organizations (CROs)
14.6.3. Others
14.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Phase
14.8.2. By Type
14.8.3. By Delivery Mode
14.8.4. By Therapeutic Area
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America Pharmacovigilance Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Phase, 2020 to 2035
15.2.1. Pre-clinical
15.2.2. Phase I
15.2.3. Phase II
15.2.4. Phase III
15.2.5. Phase IV
15.3. Market Value Forecast, by Type, 2020 to 2035
15.3.1. Spontaneous Reporting
15.3.2. Targeted Reporting
15.3.3. Cohort Event Monitoring
15.3.4. Epidemiological Studies
15.3.5. Post-Marketing Surveillance
15.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
15.4.1. In-house
15.4.2. Contract Outsourcing
15.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
15.5.1. Oncology
15.5.2. Neurology
15.5.3. Cardiology
15.5.4. Respiratory Systems
15.5.5. Autoimmune Diseases
15.5.6. Others
15.6. Market Value Forecast, by End-user, 2020 to 2035
15.6.1. Pharmaceutical & Biotechnology Companies
15.6.2. Contract Research Organizations (CROs)
15.6.3. Others
15.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Phase
15.8.2. By Type
15.8.3. By Delivery Mode
15.8.4. By Therapeutic Area
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa Pharmacovigilance Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Phase, 2020 to 2035
16.2.1. Pre-clinical
16.2.2. Phase I
16.2.3. Phase II
16.2.4. Phase III
16.2.5. Phase IV
16.3. Market Value Forecast, by Type, 2020 to 2035
16.3.1. Spontaneous Reporting
16.3.2. Targeted Reporting
16.3.3. Cohort Event Monitoring
16.3.4. Epidemiological Studies
16.3.5. Post-Marketing Surveillance
16.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
16.4.1. In-house
16.4.2. Contract Outsourcing
16.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
16.5.1. Oncology
16.5.2. Neurology
16.5.3. Cardiology
16.5.4. Respiratory Systems
16.5.5. Autoimmune Diseases
16.5.6. Others
16.6. Market Value Forecast, by End-user, 2020 to 2035
16.6.1. Pharmaceutical & Biotechnology Companies
16.6.2. Contract Research Organizations (CROs)
16.6.3. Others
16.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Phase
16.8.2. By Type
16.8.3. By Delivery Mode
16.8.4. By Therapeutic Area
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
